ObjectiveTo evaluate of the effects of vildagliptin on the levels of bone metabolism and mineral density in perimenopausal women with type 2 diabetes mellitus.
MethodsAmong 96 perimenopausal patients with type 2 diabetes, 47 patients were treated with metformin combined with vildagliptin(combination group), and 49 patients were treated with metformin(control group).The levels of hemoglobulin, osteocalcin, bone alkaline phosphatase, type Ⅰ collagen carboxyl terminal, tartrate-resistant acid phosphatase in two groups were measured using ELISA.The bone mineral density and total bone density of femoral neck, femoral shaft and greater trochanter in two groups were detected using the dual energy X-ray.
ResultsAfter treatment, the levels of the osteoprotegerin and type Ⅰ collagen carboxyl terminal in combination group were lower than those in control group(P < 0.05 to P < 0.01), the differences of the levels of osteocalcin, bone alkaline phosphatase, tartrate-resistant acid phosphatase between two groups were not statistically significant(P>0.05), and the levels of the osteoprotegerin and type Ⅰ collagen carboxyl terminal in combination group were lower than those before treatment(P < 0.05).Before treatment, the differences of the bone mineral density of left femoral neck, lumbar vertebra2-4, proximal femur and Wards triangle between two groups were not statistically significant(P>0.05).After treatment, the bone mineral density of left femoral neck, lumbar vertebra2-4, proximal femur and Wards triangle in combination group were significantly higher than those in control group(P < 0.05).
ConclusionsVildagliptin can reduce the bone resorption in perimenopausal women with type 2 diabetes, alleviate the bone resorption in condition of diabetes, and increase the bone density.Vildagliptin can be as the preferred glucose-lowering drug for perimenopausal women with type 2 diabetes, and which is worthy of clinical promotion.
DownLoad: